Form 4: Alnylam Pharmaceuticals Director Carolyn R. Bertozzi Reports Stock and Option Awards

Director Carolyn R. Bertozzi reports the acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Summary

• Carolyn R. Bertozzi, a director of Alnylam Pharmaceuticals, reported the acquisition of 775 shares of common stock represented by restricted stock units (RSUs) and a stock option to buy 1,558 shares of common stock.
• The RSUs and stock options were granted on May 8, 2025.
• The RSUs vest in full upon the earlier of the first anniversary of the grant date or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• The stock option vests in full upon the earlier of the first anniversary of the grant date or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction related to executive compensation, suggesting a neutral to slightly positive sentiment as it indicates ongoing commitment from a key director.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service by the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of stock and option awards to a company director, which is a common practice in publicly traded companies to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in the pharmaceutical industry.
• Vesting schedules tied to continued service are also typical.
• The specific number of shares and exercise price would need to be compared to similar companies and director roles to assess competitiveness.

Stakeholder Impact

• The stock and option awards align the director's interests with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.
• Employees may view the awards as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Alnylam Pharmaceuticals, Director, Carolyn R. Bertozzi, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership